CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $511,091 | -18.2% | 11,260 | +1.2% | 0.05% | -34.2% |
Q2 2023 | $624,838 | +18.2% | 11,130 | -4.8% | 0.07% | +15.9% |
Q1 2023 | $528,648 | +10.8% | 11,688 | -0.4% | 0.06% | 0.0% |
Q4 2022 | $476,906 | -44.0% | 11,732 | -10.0% | 0.06% | -51.2% |
Q3 2022 | $852,000 | +5.8% | 13,034 | -1.6% | 0.13% | +7.5% |
Q2 2022 | $805,000 | -3.0% | 13,250 | +0.2% | 0.12% | +10.1% |
Q1 2022 | $830,000 | -14.5% | 13,224 | +3.2% | 0.11% | -15.5% |
Q4 2021 | $971,000 | +5010.5% | 12,820 | +7441.2% | 0.13% | +4200.0% |
Q3 2021 | $19,000 | -29.6% | 170 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $27,000 | +440.0% | 170 | +400.0% | 0.00% | +200.0% |
Q4 2020 | $5,000 | -99.8% | 34 | +70.0% | 0.00% | 0.0% |
Q3 2020 | $2,196,000 | +20.8% | 20 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $1,818,000 | +114.4% | 20 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $848,000 | – | 20 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |